Genetic variants of PEAR1 and ischemic clinical outcomes in coronary artery disease patients: a systematic review and meta-analysis

Pharmacogenomics. 2021 Jul;22(10):641-648. doi: 10.2217/pgs-2021-0022. Epub 2021 Jun 2.

Abstract

Aim: The aim of this study was to assess the association between PEAR1 polymorphisms and ischemic clinical outcomes. Materials & methods: We searched the electronic database for articles on the relationship of PEAR1 SNPs and ischemic events in patients with coronary artery disease (CAD) up to October 2020. Results: A total of 9914 patients with CAD from six studies focusing on 12 SNPs of PEAR1 were included in this study. The A allele of rs12041331 were associated with ischemic events (odds ratio: 1.40; 95% CI: 1.04-1.88; p = 0.03). The AA homozygotes of rs2768759 was related to a higher risk of ischemic events than carriers of the C allele (odds ratio: 2.08; 95% CI: 1.09-3.97; p = 0.03). Conclusion: PEAR1 rs12041331 and rs2768759 are significantly associated with ischemic events in patients with CAD.

Keywords: SNP; antiplatelet therapy; ischemic clinical outcome; meta-analysis; platelet endothelial aggregation receptor 1.

Publication types

  • Meta-Analysis
  • Research Support, Non-U.S. Gov't
  • Systematic Review

MeSH terms

  • Cohort Studies
  • Coronary Artery Disease / drug therapy*
  • Coronary Artery Disease / genetics*
  • Dual Anti-Platelet Therapy / adverse effects
  • Dual Anti-Platelet Therapy / methods
  • Genetic Variation / drug effects
  • Genetic Variation / genetics*
  • Humans
  • Myocardial Ischemia / drug therapy
  • Myocardial Ischemia / genetics*
  • Receptors, Cell Surface / genetics*
  • Treatment Outcome

Substances

  • PEAR1 protein, human
  • Receptors, Cell Surface